Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02992288 · ClinicalTrials.gov registry record · Phase 2
A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 427
- Enrollment target
NCT02992288: Completed Phase 2 study, sponsored by Bayer.
NCT02992288 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 427 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (221% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02992288, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 427 participants
- Enrollment target
Study Summary
The objective of the study is to find the optimal dose of once daily oral neladenoson bialanate (BAY 1067197) when given in addition to standard therapy for heart failure with reduced ejection fraction (HFrEF).
Primary Outcome
Left ventricular ejection fraction (LVEF) was measured by echocardiography. Mean and standard deviation were reported.
Interventions
- DRUG Neladenoson bialanate (BAY1067197)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 427 participants |
| Start Date | 2017-02-22 |
| Est. Completion | 2018-05-16 |
| Phase | Phase 2 |
What the finished NCT02992288 record still lists
NCT02992288 is an interventional study that assigns participants to a tested intervention. The registered 427 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (221% higher).
The record links to 0 conditions, and to 1 intervention - of which Neladenoson bialanate (BAY1067197) is the first listed.
NCT02992288 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02992288 about?
NCT02992288 is a clinical study titled "A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction". The objective of the study is to find the optimal dose of once daily oral neladenoson bialanate (BAY 1067197) when given in addition to standard therapy for heart failure with reduced ejection fraction (HFrEF).
What is the current status of trial NCT02992288?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 427 participants. The study started on 2017-02-22. Estimated completion is 2018-05-16.
What interventions are being tested in trial NCT02992288?
The interventions under investigation include: Neladenoson bialanate (BAY1067197) (DRUG).
Who is sponsoring clinical trial NCT02992288?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02992288's enrollment target sits among peer trials
427 91st of 2000 higher than 1,910 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05566431 · 428 participants · NA
Benchmark Evidence Led by Latin America: Trial of Intracranial Pressure - Pediatrics
- NCT05646316 · 428 participants · Phase 3
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
- NCT05797610 · 428 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
- NCT06073626 · 428 participants · NA
Addressing Genomic Disparities in Cancer Survivors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI